Developability and Formulation of therapeutic proteins and antibodies

The successful development of biotherapeutics (e.g. antibodies) is not limited to the optimization of their biological activity, but also relies on their industrial “developability” potential. Developability criteria encompass for instance their ease of manufacture, stability during storage, and the absence of non-specific interactions. Misbehavior of drug candidates in developability assays is associated to detrimental consequences for the successful development of bioprocesses and stable drug formulations, and can even compromise drug pharmacokinetics.

In our lab, we develop new tools to enable the prediction of the developability potential of drug candidates as well as the acceleration of the formulaton design.

Contacts

Dominik Zürcher, Philippe Lenzen

Key publications

external pageH.Narayanan et al. "Design of Biopharmaceutical Formulations Accelerated by Machine Learning" Mol. Pharm., 2021

external pageM.R.G.Kopp et al. "An accelerated surface-mediated stress assay of antibody instability for developability studies" mAbs, 2020

external pageF.Grigolato et al. "Synergistic Effects of Flow and Interfaces on Antibody Aggregation" Biotechnology and Bioengineering, 2020